Alzheimer's Disease Biomarker Assay Heading for IVD Status
|
By LabMedica International staff writers Posted on 24 Jul 2017 |
|
Image: A structural representation of the ApoE protein from human blood plasma (Photo courtesy of Wikimedia Commons).
A clinical diagnostic kit that measures the concentration of the Alzheimer's disease blood biomarker APOEepsilon4 was unveiled at the Alzheimer’s Association Conference held in London, United Kingdom, from July 16-20, 2017.
The risk of developing Alzheimer’s disease (AD) is increased by three to five-folds with the presence of one epsilon4 allele and between 15 and 20 times with two alleles.
The frequency of the epsilon4 allele is approximately 40% in patients with AD. Furthermore, APOEepsilon4 carriers progress faster to clinical AD than do APOEepsilon4 non-carriers. Therefore, the presence of one or two epsilon4 alleles of the APOE gene is considered to be highly informative in epidemiological research and is currently being used for patient stratification in the latest clinical trials to evaluate AD treatments.
The Biocross (Valladolid, Spain) ApoE4 Blood Marker Assay is an immunoturbidimetry-based test. Each assay kit consists of two reagents: R1 (which contains a highly specific anti-apoE4 antibody) and R2 (a solution containing latex (polystyrene beads). During the assay, the anti-apoE4 antibody induces the agglutination of latex beads in the presence of apoE4 in the sample. This agglutination is proportional to the concentration of the apoE4 and can be measured manually or automatically with a spectrophotometer.
The ApoE4 Blood Marker Assay can be used with manageable cost in any of the clinical biochemistry analyzers that are available in most hospitals or clinical centers. The risk indicator is determined by a cost-effective and accurate blood test that is scheduled to obtain the European IVD CE mark and will be submitted for [U.S.] Food and Drug Administration approval by the end of the year.
Matthew Mittino, CEO of Biocross, said, “Introducing our risk test ApoE4 Blood Marker Assay to experts, researchers, physicians, neurologists, and specialists in neurodegenerative diseases from more than 70 countries, will mark a before and an after within clinical practice. It is a risk indicator that is already a qualitative leap, a cost-effective alternative in front of the existing ones. Now, the next step is to carry out an important information work to show its advantages to all professionals of the industry and to make it useful for improving people life quality.”
Related Links:
Biocross
The risk of developing Alzheimer’s disease (AD) is increased by three to five-folds with the presence of one epsilon4 allele and between 15 and 20 times with two alleles.
The frequency of the epsilon4 allele is approximately 40% in patients with AD. Furthermore, APOEepsilon4 carriers progress faster to clinical AD than do APOEepsilon4 non-carriers. Therefore, the presence of one or two epsilon4 alleles of the APOE gene is considered to be highly informative in epidemiological research and is currently being used for patient stratification in the latest clinical trials to evaluate AD treatments.
The Biocross (Valladolid, Spain) ApoE4 Blood Marker Assay is an immunoturbidimetry-based test. Each assay kit consists of two reagents: R1 (which contains a highly specific anti-apoE4 antibody) and R2 (a solution containing latex (polystyrene beads). During the assay, the anti-apoE4 antibody induces the agglutination of latex beads in the presence of apoE4 in the sample. This agglutination is proportional to the concentration of the apoE4 and can be measured manually or automatically with a spectrophotometer.
The ApoE4 Blood Marker Assay can be used with manageable cost in any of the clinical biochemistry analyzers that are available in most hospitals or clinical centers. The risk indicator is determined by a cost-effective and accurate blood test that is scheduled to obtain the European IVD CE mark and will be submitted for [U.S.] Food and Drug Administration approval by the end of the year.
Matthew Mittino, CEO of Biocross, said, “Introducing our risk test ApoE4 Blood Marker Assay to experts, researchers, physicians, neurologists, and specialists in neurodegenerative diseases from more than 70 countries, will mark a before and an after within clinical practice. It is a risk indicator that is already a qualitative leap, a cost-effective alternative in front of the existing ones. Now, the next step is to carry out an important information work to show its advantages to all professionals of the industry and to make it useful for improving people life quality.”
Related Links:
Biocross
Gold Member
Hematology Analyzer
Medonic M32B
Blood Glucose Test Strip
AutoSense Test
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Latest Technology News
- Cell-Sorting Device Uses Electromagnetic Levitation to Precisely Direct Cell Movement
- Embedded GPU Platform Enables Rapid Blood Profiling for POC Diagnostics
- Viral Biosensor Test Simultaneously Detects Hepatitis and HIV
- Acoustofluidic Device to Transform Point-Of-Care sEV-Based Diagnostics
- AI Algorithm Assesses Progressive Decline in Kidney Function
- Taste-Based Influenza Test Could Replace Nasal Swabs with Chewing Gum
- 3D Micro-Printed Sensors to Advance On-Chip Biosensing for Early Disease Detection
- Hybrid Pipette Combines Manual Control with Fast Electronic Aliquoting
- Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine
- Rapid Diagnostic Technology Utilizes Breath Samples to Detect Lower Respiratory Tract Infections
Channels
Clinical Chemistry
view channel
VOCs Show Promise for Early Multi-Cancer Detection
Early cancer detection is critical to improving survival rates, but most current screening methods focus on individual cancer types and often involve invasive procedures. This makes it difficult to identify... Read more
Portable Raman Spectroscopy Offers Cost-Effective Kidney Disease Diagnosis at POC
Kidney disease is typically diagnosed through blood or urine tests, often when patients present with symptoms such as blood in urine, shortness of breath, or weight loss. While these tests are common,... Read more
Hematology
view channel
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read more
Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage
Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more
Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments
Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more
Immunology
view channel
Blood-Based Liquid Biopsy Model Analyzes Immunotherapy Effectiveness
Immunotherapy has revolutionized cancer care by harnessing the immune system to fight tumors, yet predicting who will benefit remains a major challenge. Many patients undergo costly and taxing treatment... Read more
Signature Genes Predict T-Cell Expansion in Cancer Immunotherapy
Modern cancer immunotherapies rely on the ability of CD8⁺ T cells to rapidly multiply within tumors, generating the immune force needed to eliminate cancer cells. However, the biological triggers behind... Read more
Microbiology
view channel
High-Throughput Enteric Panels Detect Multiple GI Bacterial Infections from Single Stool Swab Sample
Gastrointestinal (GI) infections are among the most common causes of illness worldwide, leading to over 1.7 million deaths annually and placing a heavy burden on healthcare systems. Conventional diagnostic... Read more
Fast Noninvasive Bedside Test Uses Sugar Fingerprint to Detect Fungal Infections
Candida bloodstream infections are a growing global health threat, causing an estimated 6 million cases and 3.8 million deaths annually. Hospitals are particularly vulnerable, as weakened patients after... Read more
Pathology
view channel
New Molecular Analysis Tool to Improve Disease Diagnosis
Accurately distinguishing between similar biomolecules such as proteins is vital for biomedical research and diagnostics, yet existing analytical tools often fail to detect subtle structural or compositional... Read more
Tears Offer Noninvasive Alternative for Diagnosing Neurodegenerative Diseases
Diagnosing and monitoring eye and neurodegenerative diseases often requires invasive procedures to access ocular fluids. Ocular fluids like aqueous humor and vitreous humor contain valuable molecular information... Read more
Technology
view channel
Cell-Sorting Device Uses Electromagnetic Levitation to Precisely Direct Cell Movement
Sorting different cell types—such as cancerous versus healthy or live versus dead cells—is a critical task in biology and medicine. However, conventional methods often require labeling, chemical exposure,... Read more
Embedded GPU Platform Enables Rapid Blood Profiling for POC Diagnostics
Blood tests remain a cornerstone of medical diagnostics, but traditional imaging and analysis methods can be slow, costly, and reliant on dyes or contrast agents. Now, scientists have developed a real-time,... Read more
Industry
view channel
Qiagen Acquires Single-Cell Omics Firm Parse Biosciences
QIAGEN (Venlo, Netherlands) has entered into a definitive agreement to fully acquire Parse Biosciences (Seattle, WA, USA), a provider of scalable, instrument-free solutions for single-cell research.... Read more
Puritan Medical Products Showcasing Innovation at AMP2025 in Boston
Puritan Medical Products (Guilford, ME, USA), the world’s most trusted manufacturer of swabs and specimen collection devices, is set to exhibit at AMP2025 in Boston, Massachusetts, from November 11–15.... Read more
Advanced Instruments Merged Under Nova Biomedical Name
Advanced Instruments (Norwood, MA, USA) and Nova Biomedical (Waltham, MA, USA) are now officially doing business under a single, unified brand. This transformation is expected to deliver greater value... Read more
